The Friday 5 from Rheumatology Network is a list composed by the Rheumatology Network editorial staff aimed at highlighting relevant coverage of the latest news in rheumatology.
This week, the Friday 5 from Rheumatology Network highlights the latest in lupus, psoriatic arthritis, gout, and inflammatory arthritis covered at the European League Against Rheumatism (EULAR) 2021 Virtual Congress, as well as Rheum View: An Expert Perspective on the Management of Psoriatic Arthritis with Christopher Parker, DO.
Neil Solomons, MD, sits down to discuss his latest study, entitled “Aurinia Announces Publication of AURORA 1 Phase 3 Study Results with LUPKYNIS™ (voclosporin) in The Lancet,” which will be presented at EULAR 2021.
Data from the COSMOS study showed that 44.4% of patients who received guselkumab versus 19.8% of patients who received placebo achieved a ≥20% improvement at week 24.
As a part of our EULAR 2021 coverage, Rheumatology Network sat down with John Botson, MD, RPh, CCD, to discuss why patients with uncontrolled gout are significantly burdened with systemic co-morbid disease, why gout is more prevalent and severe in patients who have received kidney transplants, and why such few studies have been published on the use of pegloticase in organ transplant patients.
Rheumatology Networked interviewed Elena Nikiphorou, MBBS/BSc, MD (Res), to discuss her recent study that suggests self-management and resources for patients with inflammatory arthritis improve patient experience of care and outcomes by empowering and supporting them.
The impact of psoriatic arthritis on patients’ quality of life and importance of an early, accurate diagnosis.